Introduction
Testosterone therapy requires a product-specific safety plan. Discuss fertility, blood pressure, hematocrit, prostate-risk considerations, sleep, cardiovascular history, medicines, and the exact formulation before treatment.
FDA's 2025 class update retained the age-related-use limitation and added blood-pressure information across products.
Safety depends on the exact testosterone product
Testosterone is not a single product. Gels, injections, patches, oral systems, and other FDA-approved formulations have different handling and labeling details. The prescriber should identify the actual product and provide its current safety information.
Class-wide FDA communication is also relevant. In 2025, FDA announced blood-pressure labeling changes across testosterone products and retained the limitation of use for low testosterone related to aging.
Common effects are not the same as emergencies
People should report new or bothersome effects to the prescribing clinician. But chest pain, sudden shortness of breath, fainting, stroke-like symptoms, or severe allergic symptoms require urgent assessment.
A good article names the distinction because vague reassurance can delay care. It should never invite readers to decide that a serious symptom is an expected part of treatment.
Fertility requires a decision before treatment
The Endocrine Society recommends against starting testosterone therapy in patients planning fertility in the near term. That is a planning issue, not a minor side-effect footnote.
A patient should raise future family-building goals, current attempts to conceive, and semen concerns before treatment begins. The clinician can then explain the relevant options and referrals.
Monitoring turns warnings into a care plan
Guidelines call for a standardized monitoring plan that evaluates symptoms, adverse effects, compliance, testosterone, hematocrit, and prostate-risk considerations during the first year when relevant. That structure is why a telehealth service needs more than a prescription fulfillment path.
The article should not set personal thresholds or testing schedules. Results need interpretation in the context of the product, symptoms, and history.
| Question | What a provider should explain |
|---|---|
| Who monitors? | Which licensed clinician reviews symptoms and results. |
| What is checked? | The purpose of each assessment, not a generic lab bundle. |
| What happens if abnormal? | The referral or adjustment process managed by the clinician. |
| What is urgent? | When to use urgent or emergency care instead of portal messaging. |
What the 2025 FDA update did and did not say
FDA said TRAVERSE did not show an increased risk of major adverse cardiovascular outcomes in the trial population and asked sponsors to remove the boxed-warning language about increased cardiovascular outcomes. FDA also required blood-pressure information based on ambulatory blood-pressure studies.
That is not a universal safety guarantee. It does not establish appropriateness for people without a confirmed condition, for all formulations, or for every cardiovascular history.
Avoid the wrong comparisons
Social posts often combine prescribed treatment, bodybuilding use, supplements, and compounded products into one risk story. That can obscure rather than clarify the evidence. Keep the approved product, dose exposure, indication, and population visible.
If the claim is about a product not FDA-approved for the stated use, say so plainly. A provider's marketing page is not a substitute for an FDA label or guideline.
The 2025 FDA update changed the conversation, not the need for care
FDA said the TRAVERSE trial did not show an increased risk of major adverse cardiovascular events in its enrolled population, then required blood-pressure information across testosterone-product labeling after reviewing ambulatory blood-pressure studies. Those two facts should be read together.
The accurate conclusion is not that every testosterone user has the same cardiovascular profile or that blood-pressure monitoring is optional. The selected product, current label, diagnosis, and health history still determine the safety conversation.
Fertility is a tradeoff, not a minor warning
Testosterone treatment can affect sperm production. The Endocrine Society recommends against starting it in people planning fertility in the near term, which makes family-building plans one of the first decisions in an intake rather than an afterthought.
A telehealth service should make this discussion easy to have before a refill relationship begins. It should also explain when the history calls for further evaluation or a local specialist rather than treating fertility as a checkbox.
Use a two-lane symptom plan
Routine or bothersome effects belong in a prompt message to the prescriber. Chest pain, sudden shortness of breath, fainting, stroke-like symptoms, or severe allergic symptoms belong in urgent evaluation. That distinction should be visible in the treatment instructions, not hidden in a dense warning page.
The monitoring plan then gives the clinician enough information to address non-emergency concerns through the right product-specific path. That plan should name the relevant product label, the clinician responsible for reviewing concerns, and the local-care route when remote follow-up is not enough. This turns monitoring from a warning list into a practical operating plan for the patient and prescriber. It also lets the patient see whether the service is prepared to manage care after the first prescription is issued.
Common questions
- Does FDA's 2025 update mean TRT has no cardiovascular risk?
- No. FDA updated specific label language after TRAVERSE while adding blood-pressure warnings. Individual risk assessment still matters.
- Can TRT affect fertility?
- Yes. Fertility planning should be discussed before treatment begins.
- Are testosterone side effects identical for every form?
- No. Product labels and administration issues differ by formulation.
- What symptoms need urgent care?
- Chest pain, sudden shortness of breath, stroke-like symptoms, fainting, severe allergic symptoms, or another emergency concern need urgent assessment.
Current labels and follow-up matter
Testosterone safety cannot be reduced to a social-media checklist. Use the current product label, a guideline-based monitoring plan, and a clinician who knows the patient's goals and history.
Sources
- Testosterone Therapy in Men With HypogonadismEndocrine Society · Accessed 28 August 2026
Guideline for diagnostic confirmation, contraindications, fertility discussion, and monitoring.
- Evaluation and Management of Testosterone DeficiencyAmerican Urological Association · Accessed 28 August 2026
Guideline framework for assessment and management of testosterone deficiency.
- FDA issues class-wide labeling changes for testosterone productsFDA · Accessed 28 August 2026
Describes 2025 label changes, including a class-wide blood-pressure warning and retained limitation for age-related low testosterone.
- Cardiovascular Safety of Testosterone-Replacement TherapyNew England Journal of Medicine · Accessed 28 August 2026
Reports TRAVERSE results in its enrolled population.
- Testim labelFDA · Accessed 28 August 2026
Current example of FDA-approved testosterone-product labeling and warnings.
- Depo-Testosterone labelFDA · Accessed 28 August 2026
Current example of injectable testosterone labeling and warnings.
Refresh triggers
- FDA warning or label update
- New safety trial
- Guideline update